Allogene Therapeutics (NASDAQ:ALLO) EVP Zachary Roberts Sells 35,700 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 35,700 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.77, for a total transaction of $63,189.00. Following the transaction, the executive vice president directly owned 581,166 shares in the company, valued at approximately $1,028,663.82. This represents a 5.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Zachary Roberts also recently made the following trade(s):

• On Wednesday, January 21st, Zachary Roberts sold 26,269 shares of Allogene Therapeutics stock. The shares were sold at an average price of $1.56, for a total transaction of $40,979.64.

Allogene Therapeutics Stock Up 3.4%

NASDAQ:ALLO opened at $1.80 on Thursday. Allogene Therapeutics, Inc. has a twelve month low of $0.86 and a twelve month high of $3.78. The stock has a market cap of $404.51 million, a P/E ratio of -1.84 and a beta of 0.60. The firm’s fifty day simple moving average is $1.51 and its 200 day simple moving average is $1.32.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, analysts expect that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Institutional Trading of Allogene Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ALLO. Vanguard Personalized Indexing Management LLC raised its position in shares of Allogene Therapeutics by 183.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 71,688 shares of the company’s stock valued at $81,000 after buying an additional 46,398 shares during the last quarter. Patient Square Capital LP lifted its stake in Allogene Therapeutics by 11.3% in the 2nd quarter. Patient Square Capital LP now owns 2,635,000 shares of the company’s stock worth $2,978,000 after purchasing an additional 266,814 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Allogene Therapeutics during the 3rd quarter valued at about $474,000. R Squared Ltd purchased a new position in shares of Allogene Therapeutics during the second quarter valued at about $37,000. Finally, Primecap Management Co. CA increased its holdings in shares of Allogene Therapeutics by 16.0% in the second quarter. Primecap Management Co. CA now owns 5,719,140 shares of the company’s stock worth $6,463,000 after purchasing an additional 787,300 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Wall Street Zen raised Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 28th. UBS Group assumed coverage on shares of Allogene Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $8.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Allogene Therapeutics in a report on Wednesday, October 8th. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of Allogene Therapeutics in a research note on Friday, October 10th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.40.

Allogene Therapeutics News Roundup

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: The stock rallied on news the company has an extended cash runway and reported progress in its CAR‑T trials, which reduces near‑term financing risk and improves outlook for clinical milestones. Read More.
• Neutral Sentiment: Reported short‑interest figures appear anomalous (shown as 0 shares and NaN change), so there is no clear signal of rising short pressure from the latest data — treat short‑interest data as unreliable until clarified. Read More.
• Negative Sentiment: Several senior executives sold shares on Feb. 2, including CEO David D. Chang (95,269 shares at ~$1.80, ≈$171k proceeds) and other C‑suite/SVPs (multiple Form 4 filings). While each sale represents a small percentage reduction in individual holdings, coordinated insider selling can damp investor sentiment and add near‑term selling pressure. Read More.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.